

Giovanni D Aletti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9384882/publications.pdf>

Version: 2024-02-01

93
papers

5,373
citations

87401

40
h-index

97045

71
g-index

93
all docs

93
docs citations

93
times ranked

4785
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	1
2	Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers. <i>Gynecologic Oncology</i> , 2021, 160, 64-70.	0.6	6
3	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2021, 107, 100-109.	0.6	8
4	Oncologic Outcomes of Robotic Radical Hysterectomy (RRH) for Patients with Early-Stage Cervical Cancer: Experience at a Referral Cancer Center. <i>Annals of Surgical Oncology</i> , 2021, 28, 1819-1829.	0.7	7
5	Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 537-544.	1.2	4
6	Ovarian transposition in patients with cervical cancer prior to pelvic radiotherapy: a systematic review. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 360-370.	1.2	14
7	Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. <i>Gynecologic Oncology</i> , 2021, 162, 741-750.	0.6	49
8	Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study. <i>European Journal of Radiology</i> , 2020, 123, 108786.	1.2	31
9	Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 21-28.	1.2	9
10	Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	0.6	16
11	Locally advanced squamous cell carcinoma of the vulva: A challenging question for gynecologic oncologists. <i>Gynecologic Oncology</i> , 2020, 158, 208-217.	0.6	17
12	Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary. <i>Gynecologic Oncology</i> , 2020, 157, 85-88.	0.6	13
13	Neuroendocrine tumors of the cervix: an urgent call for joining forces. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 985-985.	1.2	2
14	TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR) Tj ETQq0 0 0 rgBT /Overlock 10	1.2	108
15	Do DWI and quantitative DCE perfusion MR have a prognostic value in high-grade serous ovarian cancer?. <i>Radiologia Medica</i> , 2019, 124, 1315-1323.	4.7	7
16	Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy. <i>Gynecologic Oncology</i> , 2019, 153, 684-693.	0.6	46
17	A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. <i>New England Journal of Medicine</i> , 2019, 380, 822-832.	13.9	373
18	Fibroblastic Malignant Peripheral Nerve Sheath Tumour of the Uterine Cervix: Report of a Case and Literature Review With Emphasis on Possible Differential Diagnosis. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 497-503.	0.9	12

#	ARTICLE	IF	CITATIONS
19	Lymphatic Spread of Ovarian Cancer: Can the Anatomical and Pathological Knowledge Help a Personalized Treatment?. <i>Annals of Surgical Oncology</i> , 2018, 25, 1791-1793.	0.7	2
20	Melanoma of the lower genital tract: Prognostic factors and treatment modalities. <i>Gynecologic Oncology</i> , 2018, 150, 180-189.	0.6	57
21	Radical Pelvic and Retroperitoneal Ovarian Cancer Surgery. , 2018, , 172-181.		0
22	Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. <i>European Radiology</i> , 2018, 28, 4849-4859.	2.3	100
23	Neuroendocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists. <i>Gynecologic Oncology</i> , 2017, 144, 637-646.	0.6	98
24	Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit. <i>Gynecologic Oncology</i> , 2017, 144, 468-473.	0.6	28
25	The effect of a uterine manipulator on the recurrence and mortality of endometrial cancer: a multi-centric study by the Italian Society of Gynecological Endoscopy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 592.e1-592.e11.	0.7	59
26	Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. <i>Journal of Clinical Oncology</i> , 2017, 35, 587-590.	0.8	38
27	Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies. <i>Annals of Surgical Oncology</i> , 2017, 24, 1688-1697.	0.7	29
28	Feasibility of Transabdominal Cardiophrenic Lymphnode Dissection in Advanced Ovarian Cancer: Initial Experience at a Tertiary Center. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1268-1273.	1.2	22
29	European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1534-1542.	1.2	121
30	Quality control in ovarian cancer surgery. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 96-107.	1.4	13
31	Inflammatory and Nutritional Serum Markers as Predictors of Peri-operative Morbidity and Survival in Ovarian Cancer. <i>Anticancer Research</i> , 2017, 37, 3673-3677.	0.5	28
32	Risk-reducing Salpingo-oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. <i>Anticancer Research</i> , 2017, 37, 5241-5248.	0.5	11
33	Clinical and Oncologic Outcomes of Robotic Versus Abdominal Radical Hysterectomy for Women With Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 568-574.	1.2	39
34	European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1354-1363.	1.2	104
35	Time for centralizing patients with ovarian cancer: what are we waiting for?. <i>Gynecologic Oncology</i> , 2016, 142, 209-210.	0.6	11
36	The role of surgery in recurrent endometrial cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 741-750.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 371-380.	1.2	15
38	Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2015, 137, 167-172.	0.6	142
39	There Is Nothing New Under the Sun. <i>Journal of Clinical Oncology</i> , 2015, 33, 3520-3520.	0.8	1
40	Management of endometrial cancer in Italy: A national survey endorsed by the Italian Society of Gynecologic Oncology. <i>International Journal of Surgery</i> , 2014, 12, 1038-1044.	1.1	15
41	Summary of the 18th Biannual Meeting of the European Society of Gynecologic Oncology (ESGO). <i>Gynecologic Oncology</i> , 2014, 132, 270-272.	0.6	1
42	Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience. <i>Gynecologic Oncology</i> , 2013, 130, 69-74.	0.6	15
43	The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 130, 280-283.	0.6	23
44	Multiple large bowel resections: Potential risk factor for anastomotic leak. <i>Gynecologic Oncology</i> , 2013, 130, 213-218.	0.6	65
45	The Use of CT Findings to Predict Extent of Tumor at Primary Surgery for Ovarian Cancer. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 630-632.	0.2	0
46	Intraoperative Hypothermia During Cytoreductive Surgery for Ovarian Cancer and Perioperative Morbidity. <i>Obstetrics and Gynecology</i> , 2012, 119, 590-596.	1.2	41
47	Splenectomy as Part of Primary Cytoreductive Surgery for Advanced Ovarian Cancer: A Retrospective Cohort Study. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 968-973.	1.2	17
48	Utility of closed suction pelvic drains at time of large bowel resection for ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 126, 391-396.	0.6	16
49	RE: Defining the limits of radical cytoreductive surgery in ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 509-510.	0.6	2
50	Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. <i>Gynecologic Oncology</i> , 2012, 126, 220-223.	0.6	78
51	Diaphragmatic Surgery During Primary Cytoreduction for Advanced Ovarian Cancer: Peritoneal Stripping Versus Diaphragmatic Resection. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1698-1703.	1.2	25
52	Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. <i>Gynecologic Oncology</i> , 2011, 120, 23-28.	0.6	207
53	Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: Implications for surgical staging. <i>Gynecologic Oncology</i> , 2011, 122, 536-540.	0.6	102
54	The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. <i>EMBO Molecular Medicine</i> , 2011, 3, 480-494.	3.3	67

#	ARTICLE	IF	CITATIONS
55	Improving quality of care: development of a risk-adjusted perioperative morbidity model for vaginal hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 137.e1-137.e5.	0.7	14
56	Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. <i>Gynecologic Oncology</i> , 2010, 119, 259-264.	0.6	83
57	The role of restaging borderline ovarian tumors: Single institution experience and review of the literature. <i>Gynecologic Oncology</i> , 2010, 119, 274-277.	0.6	41
58	Is There a High-Risk Subgroup of Stage I Epithelial Ovarian Cancer That Is Most Likely to Benefit From 6 Versus 3 Cycles of Adjuvant Chemotherapy?. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1125-1131.	1.2	6
59	Ovarian cancer care: it's time for "personalized" approaches. <i>Oncology</i> , 2010, 24, 728, 736.	0.4	0
60	Serine Protease HtrA1 Associates with Microtubules and Inhibits Cell Migration. <i>Molecular and Cellular Biology</i> , 2009, 29, 4177-4187.	1.1	99
61	Re: Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial. <i>Journal of the National Cancer Institute</i> , 2009, 101, 897-898.	3.0	27
62	Stage IV ovarian cancer: Disease site-specific rationale for postoperative treatment. <i>Gynecologic Oncology</i> , 2009, 112, 22-27.	0.6	36
63	Aggressive and complex surgery for advanced ovarian cancer: An economic analysis. <i>Gynecologic Oncology</i> , 2009, 112, 16-21.	0.6	44
64	Pattern of retroperitoneal dissemination of primary peritoneum cancer: Basis for rational use of lymphadenectomy. <i>Gynecologic Oncology</i> , 2009, 114, 32-36.	0.6	17
65	Random peritoneal biopsies have limited value in staging of apparent early stage epithelial ovarian cancer after thorough exploration. <i>Gynecologic Oncology</i> , 2009, 115, 86-89.	0.6	35
66	Quality Improvement in the Surgical Approach to Advanced Ovarian Cancer: The Mayo Clinic Experience. <i>Journal of the American College of Surgeons</i> , 2009, 208, 614-620.	0.2	92
67	Lymphadenectomy in endometrial cancer. <i>Lancet, The</i> , 2009, 373, 1170.	6.3	32
68	Influence of Intraoperative Capsule Rupture on Outcomes in Stage I Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2009, 114, 172-173.	1.2	1
69	Influence of Intraoperative Capsule Rupture on Outcomes in Stage I Epithelial Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2009, 113, 11-17.	1.2	83
70	MÄ4llerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers. <i>Gynecologic Oncology</i> , 2008, 108, 141-148.	0.6	56
71	Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. <i>Gynecologic Oncology</i> , 2008, 109, 303-307.	0.6	73
72	Extra-peritoneal laparoscopic para-aortic lymphadenectomy â€” A prospective cohort study of 293 patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2008, 111, 418-424.	0.6	70

#	ARTICLE	IF	CITATIONS
73	How Relevant Are ACOG and SGO Guidelines for Referral of Adnexal Mass?. <i>Obstetrics and Gynecology</i> , 2007, 110, 841-848.	1.2	73
74	Current Management Strategies for Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 751-770.	1.4	127
75	Current Management Strategies for Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 751-770.	1.4	156
76	Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. <i>Journal of Cellular Biochemistry</i> , 2007, 102, 1117-1129.	1.2	45
77	Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?. <i>Gynecologic Oncology</i> , 2007, 104, 212-216.	0.6	44
78	Analysis of factors impacting operability in stage IV ovarian cancer: Rationale use of a triage system. <i>Gynecologic Oncology</i> , 2007, 105, 84-89.	0.6	51
79	A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. <i>Gynecologic Oncology</i> , 2007, 107, 99-106.	0.6	167
80	Surgical Management of Diaphragm Disease in Ovarian Cancer. <i>Operative Techniques in General Surgery</i> , 2007, 9, 61-69.	0.0	0
81	Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 676.e1-676.e7.	0.7	285
82	Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2006, 107, 77-85.	1.2	410
83	Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 195, 1862-1868.	0.7	76
84	Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon. <i>Gynecologic Oncology</i> , 2006, 100, 33-37.	0.6	155
85	Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 100, 283-287.	0.6	150
86	Corrigendum to "Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeon" [<i>Gynecol. Oncol.</i> 100 (2006) 33-37]. <i>Gynecologic Oncology</i> , 2006, 101, 553.	0.6	1
87	Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?. <i>Gynecologic Oncology</i> , 2006, 103, 797-801.	0.6	76
88	Role of Rectosigmoidectomy and Stripping of Pelvic Peritoneum in Outcomes of Patients with Advanced Ovarian Cancer. <i>Journal of the American College of Surgeons</i> , 2006, 203, 521-526.	0.2	65
89	Importance of Surgical Aggressiveness in Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2397-2397.	0.8	5
90	Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. <i>Journal of Clinical Investigation</i> , 2006, 116, 1994-2004.	3.9	130

#	ARTICLE	IF	CITATIONS
91	Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. <i>Thrombosis and Haemostasis</i> , 2004, 91, 403-411.	1.8	28
92	Integrated FDG PET/CT in Patients with Persistent Ovarian Cancer: Correlation with Histologic Findings. <i>Radiology</i> , 2004, 233, 433-440.	3.6	162
93	Concomitant Radiotherapy and Paclitaxel for High-Risk Endometrial Cancer: First Feasibility Study. <i>Gynecologic Oncology</i> , 2001, 81, 53-57.	0.6	31